LON:NIPT

Premaitha Health PLC (NIPT.L) Competitors

GBX 9.10

+0.20 (+2.25 %)

(As of 11/6/2018)

Add

Compare

Today's Range

9.10

Now: GBX 9.10▼

9.10

50-Day Range

9.10

MA: GBX 9.10▼

9.10

52-Week Range

3.78

Now: GBX 9.10▼

14.80

Volume1.57 million shs

Average Volume1.35 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Premaitha Health PLC (NIPT.L) (LON:NIPT) Vs. AZN, GSK, SN, HIK, CTEC, and DPH

Should you be buying NIPT stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Premaitha Health PLC (NIPT.L), including AstraZeneca (AZN), GlaxoSmithKline (GSK), Smith & Nephew (SN), Hikma Pharmaceuticals (HIK), Convatec Group (CTEC), and Dechra Pharmaceuticals PLC (DPH.L) (DPH).

Premaitha Health PLC (NIPT.L) vs. AstraZeneca Stock

AstraZeneca (LON:AZN) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Profitability

This table compares AstraZeneca and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AstraZeneca	N/A	N/A	N/A
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A

Valuation & Earnings

This table compares AstraZeneca and Premaitha Health PLC (NIPT.L)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£26.62 billion	3.42	N/A	GBX 243.60	28.49
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for AstraZeneca and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	5	1	14	0	2.45
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A

AstraZeneca currently has a consensus target price of GBX 8,639.41, suggesting a potential upside of 24.27%. Given AstraZeneca's higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than Premaitha Health PLC (NIPT.L).

Summary

AstraZeneca beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) vs. GlaxoSmithKline Stock

Premaitha Health PLC (NIPT.L) (LON:NIPT) and GlaxoSmithKline (LON:GSK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares Premaitha Health PLC (NIPT.L) and GlaxoSmithKline's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A
GlaxoSmithKline	£34.10 billion	1.78	N/A	GBX 114.10	10.56

Profitability

This table compares Premaitha Health PLC (NIPT.L) and GlaxoSmithKline's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A
GlaxoSmithKline	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Premaitha Health PLC (NIPT.L) and GlaxoSmithKline, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A
GlaxoSmithKline	3	8	5	0	2.13

GlaxoSmithKline has a consensus target price of GBX 1,572.31, indicating a potential upside of 30.23%. Given GlaxoSmithKline's higher possible upside, analysts plainly believe GlaxoSmithKline is more favorable than Premaitha Health PLC (NIPT.L).

Summary

GlaxoSmithKline beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) vs. Smith & Nephew Stock

Premaitha Health PLC (NIPT.L) (LON:NIPT) and Smith & Nephew (LON:SN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Premaitha Health PLC (NIPT.L) and Smith & Nephew's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A
Smith & Nephew	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Premaitha Health PLC (NIPT.L) and Smith & Nephew, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A
Smith & Nephew	1	5	4	0	2.30

Smith & Nephew has a consensus target price of GBX 1,769.71, suggesting a potential upside of 27.32%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Premaitha Health PLC (NIPT.L).

Valuation and Earnings

This table compares Premaitha Health PLC (NIPT.L) and Smith & Nephew's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A
Smith & Nephew	£4.56 billion	2.67	N/A	GBX 51.20	27.15

Summary

Smith & Nephew beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) vs. Hikma Pharmaceuticals Stock

Premaitha Health PLC (NIPT.L) (LON:NIPT) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A
Hikma Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A
Hikma Pharmaceuticals	£2.34 billion	2.21	N/A	GBX 181.10	12.39

Analyst Ratings

This is a summary of current ratings and target prices for Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A
Hikma Pharmaceuticals	0	2	6	0	2.75

Hikma Pharmaceuticals has a consensus target price of GBX 2,478.57, suggesting a potential upside of 10.35%. Given Hikma Pharmaceuticals' higher possible upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Hikma Pharmaceuticals beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) vs. Convatec Group Stock

Convatec Group (LON:CTEC) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares Convatec Group and Premaitha Health PLC (NIPT.L)'s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Convatec Group	£1.85 billion	2.05	N/A	GBX 1.20	157.08
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Convatec Group and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Convatec Group	N/A	N/A	N/A
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Convatec Group and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Convatec Group	3	6	2	0	1.91
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A

Convatec Group presently has a consensus target price of GBX 206, indicating a potential upside of 9.28%. Given Convatec Group's higher probable upside, analysts clearly believe Convatec Group is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Convatec Group beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) vs. Dechra Pharmaceuticals PLC (DPH.L) Stock

Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dechra Pharmaceuticals PLC (DPH.L)	£566.40 million	6.50	N/A	GBX 41.40	82.27
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dechra Pharmaceuticals PLC (DPH.L)	N/A	N/A	N/A
Premaitha Health PLC (NIPT.L)	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dechra Pharmaceuticals PLC (DPH.L)	0	2	2	0	2.50
Premaitha Health PLC (NIPT.L)	0	0	0	0	N/A

Dechra Pharmaceuticals PLC (DPH.L) presently has a consensus price target of GBX 3,077.50, indicating a potential downside of 9.64%. Given Dechra Pharmaceuticals PLC (DPH.L)'s higher possible upside, research analysts clearly believe Dechra Pharmaceuticals PLC (DPH.L) is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Dechra Pharmaceuticals PLC (DPH.L) beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.